(Q38094625)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Peter Johnson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Ann L White

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

H T Claude Chan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Ruth R French

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Stephen A Beers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Martin J Glennie

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

31 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

941-948

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Immunotherapy earns its spot in the ranks of cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Anti-CD20 monoclonal antibodies: historical and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Monoclonal antibodies: versatile platforms for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Fcgamma receptors as regulators of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

The role of the CD40 pathway in the pathogenesis and treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Prospect of targeting the CD40 pathway for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

FcgammaRIV: a novel FcR with distinct IgG subclass specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Design of CD40 agonists and their use in growing B cells for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Mouse model recapitulating human Fcγ receptor structural and functional diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1398-6

10.1007/S00262-013-1398-6

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

27 February 2020

1022824791

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23543215%20AND%20SRC:MED&resulttype=core&format=json